Browse News
Filter News
Found 132 articles
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
In 2023, the FDA greenlit 55 new drugs and 34 cell and gene therapies. Follow along as BioSpace keeps you up to date on all of the FDA's decisions in 2024.
-
On the heels of a late-stage victory for its antipsychotic drug Caplyta in patients with major depressive disorder, Intra-Cellular Therapies is now offering 6.8 million shares at $73 a piece.
-
Sage Therapeutics announced Wednesday it is scrapping its Parkinson’s disease program after the company’s investigational drug showed no benefit over placebo. Phase II studies of the oral treatment will continue in Huntington’s and Alzheimer’s diseases.
-
Despite missing out on an FDA approval for major depressive disorder, Zurzuvae appears to be a strong asset for Sage Therapeutics, with high growth potential in 2024.
-
Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress
2/14/2024
Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2023.
-
Third Rock Ventures Expands Senior Team with Seasoned Biotech Executives
1/25/2024
Third Rock Ventures announced today that it has expanded its senior team with the addition and promotion of several industry leaders.
-
With recent scientific advances, milestone approvals and increased dealmaking, the future of treatment for neurological diseases looks brighter—but continued investment, collaboration and patient-focused efforts are key.
-
Sage Therapeutics to Provide Business Updates at 42nd Annual J.P. Morgan Healthcare Conference
1/8/2024
Sage Therapeutics, Inc. announced that Chief Executive Officer Barry Greene will discuss the Company’s key business drivers for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, California.
-
ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.
12/14/2023
Biogen Inc. and Sage Therapeutics, Inc. announced ZURZUVAE™ 50 mg CIV is now available by prescription for the treatment of postpartum depression for adults in the United States, with product already at specialty pharmacies and delivered to patients.
-
Despite a recent Phase II miss, Xenon Pharmaceuticals is forging ahead with its candidate for major depressive disorder, offering 8.4 million common shares for sale.
-
While the biotech’s third-quarter revenue beat Wall Street expectations, its $7.3 billion acquisition of Reata Pharmaceuticals—which closed in September—negatively impacted 2023 per-share earnings.
-
Sage Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
11/7/2023
Sage Therapeutics, Inc. reported business highlights and financial results for the third quarter ended September 30, 2023.
-
Week in Review: Amgen-Horizon Deal Moves Forward, First 10 Drugs for IRA Price Negotiation, Layof...
9/1/2023
$27.8B Amgen-Horizon deal gets FTC clearance with restrictions; the White House names first 10 drugs subject to Medicare price negotiations; Sage Therapeutics axes 40% of staff. -
Following the FDA’s recent rejection of zuranolone in major depressive disorder, Sage Therapeutics has launched a strategic reorganization initiative including a 40% reduction in headcount.
-
Sage Therapeutics Implements Strategic Reorganization to Support Plans for ZURZUVAE™ Commercial Launch and Pipeline Advancement
8/31/2023
Sage Therapeutics, Inc., announced plans to reorganize its business operations and pipeline priorities to support goals for long-term business growth, including the planned commercial launch of ZURZUVAE for women with postpartum depression in late 2023.
-
As the FDA’s recent rejection of Biogen and Sage’s zuranolone for major depressive disorder highlights, biopharma companies will need to tackle emerging challenges to bring more of these drugs to patients.
-
With a potential $509 billion up for grabs by 2028, companies including Biogen, Sage, Karuna Therapeutics and Cerevel Therapeutics are vying to bring their drugs across the regulatory finish line.
-
The FDA approved Sage and Biogen’s zuranolone Friday as the first oral medication for postpartum depression but declined to approve the application in major depressive disorder.
-
Sage Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
8/7/2023
Sage Therapeutics, Inc., a biopharmaceutical company leading the way to create a world with better brain health, reported business highlights and financial results for the second quarter ended June 30, 2023.